

Subject index

A

17-AAG, 183 (605)
ABC, 48 (148), 57 (180), 58 (184), 121 (393), 193 (641)
Adenovirus, 104 (333)
Adhesion, 18 (45), 54 (172), 184 (612)
Akt, 105 (338), 113 (365), 133 (436), 146 (478), 148 (485), 167 (551), 176 (580, 583), 180 (594), 182 (602), 183 (608), 184 (610, 611), 187 (619)
Alkylating agent, 84 (262)
Alvocidib, 90 (287)
AMG 386, 37 (111)
AMG 479, 64 (205)
Angiogenesis, 10 (18), 15 (37), 17 (42), 24 (67), 27 (77), 29 (84), 31 (90), 32 (94), 34 (101), 35 (106), 43 (131), 131 (429), 139 (449), 157 (518), 176 (580)
Animal study, 99 (316)
Anthracycline derivatives, 42 (129)
Anti-cancer agents, 125 (408), 162 (533)
Anti-resorptive agents, 158 (522)
Anti-tumor agents, 176 (581)
Antibodies, 13 (30), 23 (62), 37 (110), 38 (114, 115, 116), 40 (121), 44 (135), 61 (195, 196), 62 (200), 63 (202, 203), 64 (205, 207), 65 (208, 209), 66 (213, 214), 67 (216, 217), 68 (218), 117 (380), 175 (578), 195 (647, 648)
Antibody-drug conjugates, 67 (216)
Antiproliferative, 87 (276), 190 (631), 192 (636)
Antisense, 46 (143), 104 (334)
Apoptosis, 3 (3, 4), 4 (6), 21 (57), 41 (123), 46 (142), 52 (163), 58 (186), 76 (232), 89 (283), 117 (380), 118 (384), 119 (385), 125 (407), 128 (419), 133 (438), 143 (467, 468), 144 (469), 145 (473, 474), 147 (481), 148 (485, 486), 150 (493), 176 (580), 177 (585), 185 (613), 187 (619), 193 (642)
Ascorbate, 30 (87)
ATM, 92 (292), 141 (460)
ATN-224, 43 (132), 126 (411)
Aurora, 12 (27), 88 (278), 106 (341), 107 (343), 112 (363), 113 (364), 114 (368), 121 (394), 144 (469)
Autophagy, 68 (220), 140 (455), 146 (477)
Avastin, 20 (53)

B

B-RAF, 53 (167), 168 (553), 172 (569)
Barrett's esophagus, 153 (504)
Base excision repair, 140 (458)
Bcl-2, 3 (5), 41 (123), 104 (334), 143 (466), 144 (471), 147 (480), 185 (613)
Bcr/Abl, 54 (171), 112 (360)
Benzothiazole, 96 (306), 99 (317)
Betulinic acid, 125 (407), 157 (517)

Bevacizumab, 14 (34), 20 (53, 54), 25 (71), 27 (76), 28 (80), 37 (110), 42 (130), 62 (198), 66 (213), 80 (250)
BIBF 1120, 26 (73), 33 (96)
Bioinformatics, 109 (352)
Biomarker, 7 (7, 8), 17 (41), 24 (66), 26 (72), 36 (109), 46 (143), 67 (215, 217), 70 (225), 75 (229, 230), 90 (285), 121 (395), 144 (472), 168 (554), 186 (617)
Bioreductive, 83 (260)
BiTE, 62 (200), 70 (224)
Bladder tumor, 19 (50), 44 (136), 51 (158), 64 (206), 87 (276), 146 (478)
Brain tumor, 42 (129), 85 (269)
BRCA 1, 54 (173)
Breast Cancer, 3 (2), 17 (43), 30 (86), 44 (135), 46 (142), 47 (144), 58 (185), 63 (201), 66 (213), 67 (215), 93 (295), 101 (323), 108 (347), 117 (380), 118 (382), 119 (385), 121 (395), 129 (423), 134 (442), 146 (476), 147 (482), 154 (506), 155 (510, 512), 163 (538), 164 (542), 165 (544), 166 (549), 168 (554), 174 (574), 175 (578), 177 (584, 586), 179 (591), 180 (596), 192 (639), 193 (641)

C

c-KIT, 184 (610), 187 (622)
c-myc, 90 (286), 104 (334)
Camptothecin, 136 (446)
Cancer prevention, 10 (20)
Capecitabine, 33 (98), 94 (298, 299), 95 (303), 193 (640)
Carbonic anhydrase, 53 (168), 132 (435)
Caspase, 55 (175)
CDC-25, 89 (280)
CDC-7, 122 (398)
CDK inhibitors, 89 (282)
Cell cycle, 78 (240), 89 (283), 108 (346), 134 (439), 163 (537)
Checkpoint, 59 (189), 108 (346), 115 (373), 119 (387)
Chemo prevention, 10 (21)
Chemotherapy, 9 (17), 14 (33), 20 (53), 24 (65), 25 (69), 42 (130), 54 (169), 56 (177), 110 (355), 117 (379), 125 (406), 135 (444), 141 (461)
Chk, 107 (344)
Chromatin, 134 (440)
Cisplatin, 58 (186), 60 (191), 63 (202), 69 (221), 105 (336), 149 (487), 151 (497), 157 (516), 185 (613)
Clinical development, 9 (16), 20 (52), 70 (224), 130 (427), 140 (454), 157 (517), 188 (625)
Clinical trial, 7 (8, 9), 8 (11, 12, 13), 20 (53), 32 (92, 93), 43 (132, 133), 84 (263), 134 (439), 152 (499), 164 (540), 188 (623)
Colon cancer, 32 (95), 58 (184), 59 (189)
Colorectal cancer, 23 (63), 32 (93), 47 (145), 123 (400), 128 (418), 133 (436), 142 (465), 145 (473), 196 (650)

Combination therapy, 47 (144), 50 (157), 78 (243), 85 (266), 90 (284), 105 (337), 187 (621)
COX-2, 114 (371), 130 (425)
CTLA-1, 11 (22)
Cytotoxicity, 46 (141), 67 (216), 158 (523), 177 (586), 181 (600), 184 (610)

D

Dasatinib, 48 (150), 101 (322), 112 (360), 118 (383), 182 (603)
DC therapy, 11 (24)
DcR1, 60 (193)
Dendritic cells, 40 (120)
Denosumab, 62 (197), 63 (201)
Dimer, 95 (301), 96 (305), 131 (428)
DNA, 44 (136), 65 (211), 87 (274), 91 (288, 290), 92 (294), 93 (296), 95 (302, 304), 96 (305), 97 (309), 105 (338), 111 (358), 140 (457), 141 (460), 151 (497), 153 (502), 155 (511), 158 (521)
DNA damage, 92 (292), 96 (306), 128 (418), 188 (624)
DNA repair, 152 (498, 501), 161 (532)
Docetaxel, 20 (53), 28 (79), 49 (152), 61 (196), 94 (299), 104 (334), 119 (387), 153 (505)
Doxorubicin, 51 (159), 147 (482), 159 (525), 160 (529)
DR5, 60 (193)
Drug discovery, 116 (375), 140 (456)
Drug resistance, 55 (176), 58 (185), 81 (252A)

E

Efficacy, 20 (53), 29 (84), 31 (91), 44 (135), 47 (145), 58 (184), 62 (199), 63 (203), 80 (250), 92 (291, 294), 98 (314), 110 (356), 155 (509), 160 (528), 165 (546), 172 (567), 178 (587), 186 (617), 191 (633), 193 (641)
EGFR, 7 (8), 38 (114), 55 (174), 56 (179), 62 (198, 199), 64 (206, 207), 90 (286), 117 (379), 122 (397), 123 (399), 131 (428), 165 (543), 169 (558, 559), 172 (567), 173 (573), 174 (574), 178 (588), 179 (593), 181 (599), 182 (601), 183 (606), 196 (650)
Endometrial cancer, 120 (389)
Endothelial cells, 15 (37), 20 (54), 29 (82), 101 (323)
Epidemiology, 10 (19)
Epidermal growth factor receptor, 31 (89), 62 (198), 67 (217), 131 (428), 166 (548), 181 (599), 182 (604)
Erlotinib, 14 (34), 20 (53), 42 (130), 62 (198), 80 (250), 126 (412), 165 (546), 167 (550), 179 (593), 182 (603), 183 (607), 185 (614)
Estrogen receptor, 93 (295), 154 (507), 177 (584)
Ets factor, 39 (119)
Ewing tumor, 78 (241), 112 (360)

F

Falvopiridol, 152 (501)
FAP, 160 (527)
Flavopiridol, 90 (287)
5-fluorouracil, 28 (80), 57 (181)

G

G-protein, 48 (148)
G-quadruplex, 131 (430)
Gefitinib, 55 (174), 58 (184), 59 (187), 146 (478)
Gemcitabine, 63 (202), 160 (528), 162 (534), 184 (610)
Gene expression, 18 (48), 29 (82), 87 (274), 109 (352), 135 (445), 151 (496), 184 (610)
Gene therapy, 104 (333), 106 (340)

Genes, 18 (48), 26 (74), 32 (95), 46 (142), 75 (227), 87 (273), 90 (287), 94 (298), 100 (320), 105 (336, 338), 118 (382), 126 (409), 142 (462), 147 (480)
Genetic engineering, 18 (46), 169 (559)
Genetic marker, 75 (228)
Genetics, 107 (344), 123 (400), 135 (444)
Genotoxic stress, 91 (289)
GIST, 21 (57), 58 (183), 118 (383), 168 (555), 171 (563), 173 (570)
Gleevec, 3 (5), 100 (321)
Glioblastoma, 17 (42), 22 (58), 86 (272), 113 (365), 157 (518)
Glioma, 103 (329), 104 (335), 147 (480), 161 (531)
Green tea, 41 (124)
Growth prevention, 148 (484)

H

HDAC, 52 (162), 53 (166), 90 (284), 92 (293), 93 (295), 94 (300), 98 (312), 100 (319), 109 (350, 351), 113 (367), 116 (375, 376), 119 (388), 121 (394), 154 (506), 177 (584)
Head and neck cancer, 114 (371)
Heat Shock Protein, 173 (570)
Hepatocellular carcinoma, 14 (34), 20 (54), 87 (273), 114 (370), 120 (391), 127 (416), 136 (448), 148 (485), 185 (615)
HER-2/neu, 38 (115), 44 (135), 102 (325)
High throughput screening, 130 (426)
Histone deacetylase inhibitor, 52 (162), 92 (293), 93 (295), 94 (300), 98 (312), 109 (350, 351), 113 (367), 119 (388), 121 (394), 154 (506), 177 (584), 182 (604)
Histone methyltransferase, 97 (310), 130 (426)
Hsp90, 110 (354), 121 (394), 128 (419), 165 (543, 544, 545), 168 (555), 173 (570), 183 (605)
Hypoxia, 9 (15), 17 (44), 18 (48), 82 (256, 258), 83 (259, 260), 84 (263), 161 (531), 189 (629)

I

IAP, 4 (6), 112 (361)
IDO, 11 (25)
IGF, 17 (44), 61 (195, 196), 64 (205, 207), 130 (425), 165 (546), 171 (564), 178 (590), 195 (648)
Imaging, 8 (11), 43 (131, 133), 45 (140), 47 (146), 65 (211), 99 (315), 139 (449, 450, 451, 452), 143 (468), 149 (490)
Imatinib, 28 (79), 79 (246), 81 (252), 134 (441), 171 (563), 173 (572)
Imidazole, 12 (28)
Immunotherapy, 38 (116), 39 (118), 84 (265), 85 (268), 86 (272)
Indenoisoquinoline, 49 (151)
Induction, 38 (116), 41 (125), 55 (175), 110 (353), 117 (380), 131 (428), 143 (467, 468), 150 (492), 188 (624)
Inhibitor, 4 (6), 7 (8), 12 (26, 27), 13 (29LB1), 15 (35, 37), 16 (38), 17 (41), 19 (49, 50, 51), 22 (58), 24 (68), 25 (71), 26 (72, 73), 27 (75), 29 (81, 83, 84), 30 (85, 86), 31 (91), 32 (93), 33 (96, 97), 35 (105), 36 (108), 37 (111), 40 (122), 43 (132), 52 (163), 53 (166, 167, 168), 61 (194), 88 (278), 90 (284), 97 (311), 100 (319), 106 (341), 112 (363), 113 (364), 114 (369), 116 (376), 122 (398), 123 (401), 127 (414, 415), 131 (431), 132 (434), 141 (459), 152 (499), 154 (508), 156 (515), 170 (561), 171 (563), 172 (566, 568, 569), 173 (572), 174 (576), 175 (579), 176 (582)
Insulin-like growth factor, 61 (195, 196), 66 (214), 131 (428), 177 (586), 180 (595)
Interferon-alpha, 39 (117)
Interferon-gamma, 147 (482)

Interleukin, 18 (45), 34 (101), 39 (117), 84 (265), 85 (267), 268, 86 (271), 88 (277)

Intestinal tumorigenesis, 42 (127)

Invasion, 16 (39), 30 (85), 32 (95), 69 (222), 82 (255), 158 (520), 173 (571), 184 (612)

Irinotecan, 23 (63), 48 (149), 49 (153), 50 (156), 135 (444), 445, 136 (447)

Irofulven, 94 (299), 95 (303)

K

Kinase inhibitors, 13 (30, 32), 14 (33), 53 (165), 105 (337), 127 (413), 131 (428), 141 (460), 169 (558), 170 (560), 173 (570)

KIT, 58 (183), 68 (219), 79 (246), 173 (572), 184 (610), 187 (622)

L

Legislation, 76 (235)

Leteprinim, 69 (221)

Leukemia, 55 (176), 57 (182), 150 (493), 151 (496), 152 (498), 172 (566)

Liver cancer, 22 (59), 31 (89)

Lung cancer, 13 (29), 20 (53), 106 (339), 117 (380), 123 (399), 128 (417, 419), 130 (427), 131 (428), 182 (604), 192 (639)

Lymphoma, 45 (139), 51 (160), 101 (324), 116 (377, 378), 119 (388), 126 (409), 132 (432), 142 (463), 147 (481)

M

Mapatumumab, 63 (202)

MAPK, 167 (550), 168 (553), 178 (589), 187 (619)

Marker, 43 (132), 99 (318), 116 (375), 121 (393), 144 (469)

Mass spectrometry, 102 (327)

Matrix metalloproteinase, 24 (67, 68), 128 (417)

MDM2, 52 (164), 180 (597)

Melanoma, 22 (61), 26 (74), 34 (101), 68 (218), 84 (264, 265), 87 (275), 92 (293), 106 (340), 109 (349), 115 (374), 126 (411), 161 (532), 170 (562), 171 (565), 176 (583), 178 (589)

Metastasis, 15 (36, 37), 17 (43), 22 (59), 27 (77), 30 (86), 34 (101), 37 (110), 50 (157), 63 (201), 69 (222), 81 (253), 103 (331), 117 (381), 131 (429), 166 (549), 174 (575)

Microarray, 44 (136), 87 (274), 144 (472)

Mitochondria, 125 (407)

Mitoxantrone, 94 (299)

Model, 69 (223)

Molecular targets, 127 (416)

Monoclonal antibodies, 13 (30, 31), 14 (33), 64 (204), 65 (210)

mTOR, 15 (35), 112 (362), 146 (477), 164 (541), 168 (554), 175 (578), 177 (586), 180 (594), 181 (598), 183 (606), 187 (621)

N

N-sulfonyluracil, 99 (317)

Nanoparticles, 47 (146), 48 (148), 52 (161)

Nemorubicin, 152 (500)

Neuroblastoma, 54 (169), 78 (240), 112 (360), 121 (393), 149 (487), 156 (514)

Non-small cell lung cancer, 16 (40), 20 (53), 32 (92), 35 (103), 38 (114), 42 (130), 59 (187), 103 (330), 117 (380, 381), 131 (428), 134 (439), 142 (464), 147 (483), 177 (585), 183 (606), 185 (613), 186 (618), 189 (628), 194 (643, 645)

NQO1, 41 (125)

O

Oligonucleotides, 92 (294), 104 (334)

Oral administration, 33 (97), 106 (342), 124 (404, 405)

Ovarian cancer, 60 (190), 65 (210), 97 (308), 102 (326), 189 (628)

Overexpression, 123 (402), 179 (591)

Oxaliplatin, 32 (93), 59 (188, 189), 94 (298), 142 (465)

P

p53, 52 (164), 61 (194), 75 (231), 76 (232, 233, 234), 110 (353), 119 (385), 143 (467), 144 (470), 145 (473), 148 (486), 157 (516), 163 (539)

Paclitaxel, 16 (40), 31 (89), 32 (92), 37 (110), 51 (159), 59 (187), 80 (251), 111 (357), 153 (505), 165 (543), 183 (607), 191 (633, 635), 192 (637), 194 (643, 645)

Pancreatic cancer, 42 (128), 64 (204), 100 (320), 110 (355), 119 (386), 130 (425), 184 (610)

PBR ligands, 157 (519)

PD-1, 11 (22)

Pediatric oncology, 34 (102), 76 (235), 77 (236, 237, 238, 239), 78 (242, 243), 79 (244, 245, 247), 80 (248/249), 84 (262), 98 (313), 101 (322), 150 (491), 151 (496)

Pemetrexed, 20 (53), 23 (64)

Peptide-conjugate, 128 (417)

Peptides, 37 (112)

Peroxiredoxin, 120 (392)

Phagocytic activity, 159 (524)

Pharmacogenomic, 135 (444)

Pharmacological studies, 12 (26), 13 (29LB1), 26 (72, 73), 27 (75), 29 (81, 83), 32 (92), 33 (96, 97), 36 (109), 48 (149, 150), 49 (153), 50 (155), 56 (178), 57 (181), 60 (192), 61 (196), 63 (201), 65 (208), 66 (212), 70 (226), 78 (243), 80 (248/249), 84 (263), 88 (279), 90 (285), 93 (297), 94 (298), 106 (342), 108 (346), 111 (357, 358, 359), 114 (368), 123 (401), 124 (404, 405), 126 (412), 132 (433, 434), 134 (442), 142 (464), 153 (503), 156 (513), 165 (545), 167 (552), 182 (602), 183 (607), 186 (617), 191 (634), 193 (642)

Phase I studies, 12 (26, 27), 13 (29LB1), 15 (35), 16 (38), 17 (41), 19 (51), 23 (64), 26 (72), 29 (83), 32 (93), 33 (97, 98), 34 (99), 36 (108), 42 (129), 44 (134), 45 (139), 57 (181), 61 (196), 62 (198), 63 (201, 202), 66 (212), 68 (218), 70 (226), 78 (243), 79 (245), 80 (248/249), 83 (261), 84 (263, 265), 86 (270), 89 (281), 90 (285), 93 (297), 94 (300), 96 (307), 106 (340, 342), 107 (343), 108 (346, 348), 111 (357, 358), 113 (366), 114 (370), 118 (383), 124 (405), 132 (432), 142 (463, 465), 149 (489), 153 (503), 167 (550), 173 (570, 573), 183 (607), 187 (621), 192 (638), 193 (640), 194 (644), 195 (647, 648, 649), 196 (651)

Phase II studies, 14 (34), 16 (40), 18 (47), 20 (53), 24 (65), 35 (103), 38 (113), 42 (130), 59 (187), 68 (218), 79 (246), 80 (248/249), 86 (270), 94 (299), 112 (362), 134 (439), 142 (465), 149 (489), 164 (541, 542), 190 (632)

PI3-Kinase, 80 (251)

PK/PD, 53 (166)

Platelet, 27 (76)

Platelet-derived growth factor receptor, 28 (79)

PPTP, 34 (102), 77 (239), 98 (313), 101 (322)

Prednisone, 94 (299)

Prodrugs, 50 (154)

Prostate cancer, 18 (45), 28 (79), 38 (113), 39 (119), 40 (122), 41 (126), 94 (299), 95 (303), 104 (334), 108 (347), 109 (350, 351), 112 (362), 120 (390), 146 (477), 159 (526), 161 (530), 163 (539), 175 (577), 180 (595), 184 (611)

Proteasome inhibitor, 56 (179), 122 (397)
Proteomics, 75 (229)
PSA, 159 (526), 160 (529)
PTEN, 146 (477), 179 (592)
PXD-101, 57 (181), 100 (319), 109 (351), 111 (357)

R

Radiation, 29 (84), 36 (107), 162 (534), 163 (536, 537)
Radiotherapy, 14 (33), 23 (63), 62 (199), 65 (211), 153 (502), 161 (531), 162 (535)
RAF, 105 (338), 176 (582), 184 (609)
RANK, 108 (347), 150 (494), 166 (549)
Rapamycin, 50 (157), 133 (437), 167 (551), 176 (583)
RAR/RXR, 151 (495)
Reactive oxygen species, 154 (507)
Receptor, 3 (4), 15 (35, 36), 21 (57), 22 (60), 28 (79), 31 (89), 32 (93), 35 (104, 106), 36 (108), 42 (127), 48 (148), 61 (195, 196), 62 (197, 198), 64 (205), 66 (214), 68 (219), 85 (267), 96 (306), 116 (376), 126 (410), 128 (420), 145 (475), 159 (525), 172 (567), 174 (576), 175 (577, 578), 187 (620), 195 (647, 648), 196 (651)
RECIST, 7 (10)
Regression, 44 (137), 84 (264), 169 (559), 175 (579), 178 (590)
Renal cell carcinoma, 18 (48), 21 (55), 39 (117), 80 (250), 84 (265), 85 (266)
Robotic, 102 (328)

S

Sample transport medium, 45 (138)
Sarcoma, 112 (360), 113 (367), 125 (406), 134 (440), 145 (474), 180 (597), 181 (599), 187 (620)
Satraplatin, 185 (614)
Selaciclib, 88 (279)
Semilog plot, 44 (137)
Signal transduction, 139 (451)
Simvastatin, 48 (150)
Solid tumors, 79 (246), 113 (366)
Sorafenib, 18 (47, 48), 33 (98), 35 (105), 85 (266), 123 (399), 133 (437), 167 (550), 171 (563), 173 (572), 178 (589), 184 (610)
Src family kinases, 117 (379), 178 (590)
Stat3, 55 (174), 166 (547), 169 (556)
Statins, 87 (275), 129 (424)
Stem cells, 3 (2), 13 (29), 85 (269), 129 (422), 139 (453)
Structure activity relationship, 169 (556)
Sunitinib, 21 (56, 57), 22 (58), 27 (78), 39 (117), 85 (266), 133 (437)
Surgical resection, 169 (557)
Survivin, 13 (29LB1), 104 (332), 116 (377), 122 (396), 131 (428), 149 (488)

T

Targeted therapeutics, 3 (1), 19 (49), 47 (144), 65 (211), 75 (229), 77 (237), 82 (254), 95 (304), 107 (345), 115 (372), 124 (403), 126 (409), 128 (420), 140 (455), 161 (530), 167 (550), 196 (650)
Targeted therapeutics, 67 (217)

Taxanes, 56 (178), 59 (187), 98 (314), 105 (337), 112 (362), 190 (631), 193 (641), 194 (644)
Taxol, 47 (147), 177 (586), 195 (646)
Telomerase, 188 (623, 626), 189 (628)
Telomere, 131 (430), 140 (454), 188 (624, 625), 189 (627)
Temozolomide, 85 (269)
Thymidylate synthase, 142 (462)
Tirapazamine, 82 (257, 258), 83 (260)
Topoisomerase I, 92 (293), 95 (302), 135 (443)
Topoisomerase II, 61 (194), 150 (493)
Topotecan, 134 (441)
TRAIL, 3 (4), 63 (202), 145 (474), 146 (478)
TRAIL/Apo2L, 3 (3), 184 (611)
Transcription, 31 (88), 76 (232), 90 (287), 91 (289), 104 (333, 335), 134 (440), 147 (480), 149 (489), 156 (515), 174 (576)
Tregs, 11 (23)
Tubulin, 189 (629), 192 (636)
Tumor model, 29 (84), 144 (469)
Tumor necrosis factor, 145 (474, 475)
Tyrosine kinase, 13 (30, 32), 14 (33), 15 (35), 16 (38), 19 (49), 21 (57), 27 (75), 31 (91), 36 (107, 108), 55 (174), 123 (399), 126 (410), 131 (428), 169 (558), 170 (560), 172 (567), 173 (570, 571), 175 (577, 578), 178 (588), 182 (603), 183 (606), 186 (618), 187 (620, 621, 622)

U

Ubiquitin, 107 (345), 155 (511), 166 (548)

V

Vaccine, 38 (114)
Vascular targeting, 9 (14), 113 (366)
VEGF, 15 (35, 37), 16 (38), 17 (41, 44), 19 (49, 51), 20 (52), 24 (66), 25 (70), 26 (72, 73), 27 (75, 76, 78), 28 (80), 31 (88, 90, 91), 32 (93), 34 (100), 35 (104, 106), 36 (107), 37 (110), 62 (198), 64 (207), 79 (247), 124 (405), 162 (535), 178 (588), 183 (606), 187 (621), 195 (647)
VEGF inhibitor, 34 (100, 102)
VEGF receptor, 31 (90), 187 (621)
Velcade, 100 (321)
Vitamins, 30 (87), 42 (128), 129 (421)

X

Xenograft model, 23 (63), 47 (145), 50 (156), 53 (165), 66 (213), 116 (378), 125 (406), 133 (437), 143 (468), 160 (528), 178 (590), 186 (617), 189 (628)
Xenografts, 25 (71), 34 (100), 37 (110), 52 (161), 64 (205), 97 (308), 105 (336), 149 (487), 153 (505), 157 (518), 162 (535), 165 (543, 546), 176 (580), 179 (592, 593), 186 (616), 190 (630), 191 (633), 192 (637)
XIAP, 46 (143), 146 (478), 150 (491)
Xiapuradamib, 130 (427)

Z

ZIO-101, 146 (479)